Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2024

23-04-2024 | Correspondence

Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms

Authors: Syeda Dua e Zehra Zaidi, Syeda Mahrukh Fatima Zaidi, Burhanuddin Sohail Rangwala

Published in: Annals of Hematology | Issue 6/2024

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Streuer A, Jann JC, Boch T, Mossner M, Riabov V, Schmitt N, Altrock E, Xu Q, Demmerle M, Nowak V, Oblaender J, Palme I, Weimer N, Rapp F, Metzgeroth G, Hecht A, Höger T, Merz C, Hofmann WK, Nolte F, Nowak D (2024) Feb 27 Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms. Ann Hematol. https://​doi.​org/​10.​1007/​s00277-024-05664-5. Epub ahead of print. PMID: 38413410
2.
Boch T, Luft T, Metzgeroth G, Mossner M, Jann JC, Nowak D, Meir F, Schumann C, Klemmer J, Brendel S, Fricke H, Kunz C, Weiß C, Hofmann WK, Nolte F (2018) Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS. Leuk Res 68:62–69 Epub 2018 Mar 10. PMID: 29549809CrossRefPubMed
3.
Radujkovic A, Boch T, Nolte F, Nowak D, Kunz C, Gieffers A, Müller-Tidow C, Dreger P, Hofmann WK, Luft T (2020) Clinical response to the CD95-Ligand inhibitor asunercept is defined by a pro-inflammatory serum Cytokine Profile. Cancers (Basel) 12(12):3683. https://​doi.​org/​10.​3390/​cancers12123683 PMID: 33302451; PMCID: PMC7764464CrossRefPubMed
4.
Metadata
Title
Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms
Authors
Syeda Dua e Zehra Zaidi
Syeda Mahrukh Fatima Zaidi
Burhanuddin Sohail Rangwala
Publication date
23-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05748-2

Other articles of this Issue 6/2024

Annals of Hematology 6/2024 Go to the issue

Research

Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China

Original Article

Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

Original Article

Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients

Letter to the Editor

Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia

Letter to the Editor

Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms

Correspondence

Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits